作者
Neslihan Yilmaz, Hakan Emmungil, Sercan Gucenmez, Gulsen Ozen, Fatih Yildiz, Ayşe Balkarli, Gezmis Kimyon, Belkis Nihan Coskun, Ismail Dogan, Omer Nuri Pamuk, Sule Yasar, Gozde Yildirim Cetin, Ayten Yazici, Serpil Ergulu Esmen, Yonca Cagatay, Sema Yilmaz, Ayse Cefle, Mehmet Sayarlioglu, Timucin Kasifoglu, Omer Karadag, Yavuz Pehlivan, Ediz Dalkilic, Bunyamin Kisacik, Veli Cobankara, Eren Erken, Haner Direskeneli, Kenan Aksu, Sule Yavuz
发表日期
2015/9/1
期刊
The Journal of rheumatology
卷号
42
期号
9
页码范围
1661-1666
出版商
The Journal of Rheumatology
简介
Objective
To assess bladder toxicity of cyclophosphamide (CYC) and uroprotective effect of mesna in rheumatic diseases.
Methods
Data of 1018 patients (725 women/293 men) treated with CYC were evaluated in this retrospective study. All of the following information was obtained: the cumulative CYC dose, route of CYC administration, duration of therapy, concomitant mesna usage, and hemorrhagic cystitis. Cox proportional hazard model was used for statistics.
Results
We identified 17 patients (1.67%) with hemorrhagic cystitis and 2 patients (0.19%) with bladder cancer in 4224 patient-years. The median time for diagnosis to hemorrhagic cystitis was 10 months (4–48) and bladder cancer was 8 years (6–10.9). There were 583 patients (57.2%) who received mesna with intravenous CYC therapy. We observed similar incidence rate for hemorrhagic cystitis in both patient groups concomitantly treated with or without …
学术搜索中的文章
N Yilmaz, H Emmungil, S Gucenmez, G Ozen, F Yildiz… - The Journal of rheumatology, 2015